Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-25 @ 2:05 AM
NCT ID:
NCT00057460
Eligibility Criteria:
INCLUSION CRITERIA:
Study subjects must be 18-45 years old (inclusive).
Study subjects must give informed consent in writing prior to entering the study.
Study subjects must be able to participate for the full term of the trial.
EXCLUSION CRITERIA:
Any of the following conditions is cause for exclusion from the study:
Any illness requiring chronic drug therapy with one of the following drugs: Depakote (valproic acid), Hismanal (astemizole), Propulsid (cisapride), Allegra (fexofenadine), Seldane (terfenadine), Luvox (fluvoxamine), Felbamate (felbatol), Tiagabine (vigabatrin), hepatic enzyme inducers such as Tagamet (cimetidine), and -azole antifungals such as Flagyl (metronidazole), Diflucan (fluconazole), and Nizoral (ketoconazole).
History of a psychiatric disorder, under the care of a psychiatrist, or on medications for treatment of a psychiatric disorder.
Known sensitivity or allergy to talampanel or related compounds.
Use of illicit drugs, binge drinking, or alcoholism as per medical history inventory.
Exposure to any other investigational drug within 12 weeks prior to randomization.
Magnetic stimulation will not be performed in people who have pacemakers, implanted pumps or stimulators, or who have metal objects inside the eye or skull.
Being under the age of 18 years or over the age of 45 years.
Pregnant or lactating.
Cardiac, pulmonary, or neurological problems as determined by medical history, EKG, and examination by a physician.
Healthy Volunteers:
True
Sex:
ALL
Study:
NCT00057460
Study Brief:
Protocol Section:
NCT00057460